A Prospective Randomised Comparative Four-arm Intervention Study of Efficacy and Safety of Saroglitazar and Vitamin E in Patients With Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH)-SVIN TRIAL

脂肪性肝炎 医学 内科学 胃肠病学 脂肪肝 酒精性肝病 疾病 肝硬化
作者
Bilal Ahmad Mir,Brij Sharma,Rajesh Sharma,Vishal Bodh,Ashish Chauhan,Tahir Majeed,Inaamul Haq,Neetu Sharma,Dikshant Sharma
出处
期刊:Journal of clinical and experimental hepatology [Elsevier BV]
卷期号:14 (5): 101398-101398 被引量:10
标识
DOI:10.1016/j.jceh.2024.101398
摘要

Abstract

Background and Aim

Vitamin E is widely prescribed for Non-alcoholic steatohepatitis (NASH).Saroglitazar, a novel dual PPAR ɑ/γ agonist, is approved in India for Non-alcoholic fatty liver disease(NAFLD).No head-to-head comparative study for vitamin E and saroglitazar is available. We studied the efficacy and safety of saroglitazar and vitamin E in NAFLD/NASH.

Materials and Methods

We prospectively randomised 175 NAFLD patients into four arms as; Saroglitazar 4mg daily alone (n=44),vitamin E 800IU daily alone (n=41), vitamin E and saroglitazar combination(n=47) and control arm (n=43). All the baseline variables including Liver stiffness measurement (LSM) and Controlled attenuation parameter (CAP) were recorded.Reassessment was done after 24 weeks of treatment.

Results

The mean age and BMI was 45±11 years and 26±3.6 kg/m2 respectively. Compared to control, the decrease in ALT levels with saroglitazar, vitamin E and combination therapy was significant (95% CI, 6.27-28.25,p=0.002, 95% CI, -3.39-18.88, p=0.047 and 95% CI 8.10-29.54,p=0.001 respectively).The reduction in CAP was significant with saroglitazar and combination therapy (95% CI, -31.94-11.99,p=0.015 and 95% CI, -10.48-30.51,p=0.026 respectively).Only combination therapy shows significant reduction in LSM (95% CI, 0.41-1.68,p=0.001).Among glycaemic parameters, both saroglitazar alone and combination therapy significantly improved HBA1C levels (P=0.001 and P=0.015) and only combination therapy significantly improved HOMA-IR (P=0.047).Saroglitazar alone showed significant reduction in TG and LDL levels (P=0.038 and P=0.018), and combination therapy showed significant increase in HDL levels (P=0.024).

Conclusions

Combination of Saroglitazar and vitamin E showed statistically significant reduction of LSM and CAP along with biochemical, glycaemic and lipid parameters.

Clinical Trial Registry India no

(CTRI/2022/01/039538).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
V_发布了新的文献求助10
刚刚
刚刚
刚刚
刚刚
超级无敌发布了新的文献求助30
1秒前
YH发布了新的文献求助10
1秒前
夏木发布了新的文献求助10
1秒前
科研通AI65的应助被一路生花采纳,获得10
2秒前
完美世界的应助被Rambo采纳,获得10
3秒前
遥知马完成签到,获得积分10
3秒前
传奇3的应助被吴xl采纳,获得10
4秒前
4秒前
NexusExplorer的应助被原儿采纳,获得10
5秒前
5秒前
5秒前
panjiuer关注了科研通微信公众号
6秒前
晨晨的应助被LL采纳,获得10
6秒前
8秒前
kuangrenluoli完成签到,获得积分10
9秒前
小马甲的应助被Tobin采纳,获得10
9秒前
10秒前
狂人萝莉完成签到,获得积分10
11秒前
11秒前
12秒前
12秒前
锐锐发布了新的文献求助10
12秒前
13秒前
Lucas的应助被番茄米线儿采纳,获得10
13秒前
魏同心发布了新的文献求助10
14秒前
昏睡的帆布鞋完成签到 ,获得积分10
14秒前
科研通AI6.4的应助被温柔依云采纳,获得10
16秒前
orixero的应助被leo采纳,获得10
16秒前
hhhhliii发布了新的文献求助10
16秒前
16秒前
淼淼发布了新的文献求助10
17秒前
狂野水壶完成签到 ,获得积分10
17秒前
17秒前
ywzwszl完成签到,获得积分0
17秒前
Whispers完成签到,获得积分10
17秒前
zhouye完成签到,获得积分10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193156
求助须知:如何正确求助?哪些是违规求助? 9579416
关于积分的说明 21865319
捐赠科研通 7792722
什么是DOI,文献DOI怎么找? 3437168
关于科研通互助平台的介绍 2560670
邀请新用户注册赠送积分活动 2483977